DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and twelve approved drugs.

There are sixty-eight US patents protecting TEVA drugs. There are forty-three tentative approvals on TEVA drugs.

There are seven hundred and eighty-nine patent family members on TEVA drugs in forty-six countries and five hundred and forty-five supplementary protection certificates in fourteen countries.

Summary for Teva

International Patents:	789
US Patents:	68
Tradenames:	471
Ingredients:	414
NDAs:	712
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	GRANISETRON HYDROCHLORIDE	granisetron hydrochloride	INJECTABLE;INJECTION	078392-001	Dec 31, 2007	AP	RX	No	Yes
Teva	METOPROLOL TARTRATE	metoprolol tartrate	TABLET;ORAL	074143-001	Sep 30, 1994		DISCN	No	No
Teva Womens	ADDERALL 15	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-013	Aug 31, 2000		DISCN	Yes	No	6,384,020*PED				Y
Teva	PROPOXYPHENE COMPOUND 65	aspirin; caffeine; propoxyphene hydrochloride	CAPSULE;ORAL	089025-001	Mar 29, 1985		DISCN	No	No
Teva	PENTOXIFYLLINE	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	075199-001	Sep 3, 1999		DISCN	No	No

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	PROAIR HFA	albuterol sulfate	AEROSOL, METERED;INHALATION	021457-001	Oct 29, 2004	5,695,743
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-001	May 16, 2006	6,126,968
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995	4,933,168
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,620,847
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-002	Jan 27, 2017	6,446,627

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.5 mg and 1 mg		2010-05-17
	Tablets	0.625 mg		2009-03-02
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	1.25 mg		2008-11-03
	Tablets	0.3 mg, 0.45 mg and 0.9 mg		2009-03-19
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

Non-Orange Book US Patents for Teva

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,989,436	Estrogenic compounds and pharmaceutical formulations comprising the same
9,108,010	Dose counters for inhalers, inhalers and methods of assembly thereof
9,526,850	Dose counters for inhalers, inhalers and methods of assembly thereof
8,338,396	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
7,842,687	Cephalotaxane derivatives and their processes of preparation and purification

International Patents for Teva Drugs

Country	Document Number	Estimated Expiration
Peru	00672002
Hong Kong	1103366
Spain	2526118
China	102186848
Canada	2727926

Supplementary Protection Certificates for Teva Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2016	Austria		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, INSVBESONDERE DARUNAVIR-ETHANOLAT; REGISTRATION NO/DATE: EU/1/14/967 (MITTEILUNG) 20141121
C/GB02/031	United Kingdom		PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
C/GB03/023	United Kingdom		PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404
90035-0 98910359	Sweden		PRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715
00133	Netherlands		PRODUCT NAME: OLMESARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN DE CARBOXYGROEP GEKOZEN UIT DE VOLGENDE : EEN ALKYLGROEP 1-4 KOOLSTOFATOMEN, EEN BENZYLGROEP, EEN ALKANOYLOXYALKYLGROEP WAARIN HET ALKANOYLDEEL 1-5; NATL. REGISTRATION NO/DATE: RVG 28785-RVG 28787 20030527; FIRST REGISTRATION: DE 502.02.00.00,502.02.01.00, 502.02.02.00 20020813

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms